No data to show
XNAS
XRTX
Market cap3mUSD
Jun 06, Last price
0.92USD
1D
0.00%
1Q
-5.67%
IPO
-90.57%
Name
XORTX Therapeutics Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
27.64%
Rev. gr., 5y
%
Revenues
0k
Net income
0k
CFO
-7m
Dividend
Jan 31, 20140.0001 USD/sh
Earnings
Aug 12, 2025
Profile
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | 8,785 | |||||||
Unusual Expense (Income) | ||||||||
NOPBT | (8,785) | |||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | (8,785) | |||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 5,051 | |||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | 12 | 66 | ||||||
Long-term debt | 12 | 89 | ||||||
Deferred revenue | ||||||||
Other long-term liabilities | 531 | 3,847 | ||||||
Net debt | (3,400) | (10,253) | ||||||
| Cash flow | ||||||||
Cash from operating activities | (6,583) | |||||||
CAPEX | ||||||||
Cash from investing activities | (46) | |||||||
Cash from financing activities | (361) | 4,738 | ||||||
FCF | (294) | (8,877) | ||||||
| Balance | ||||||||
Cash | 3,423 | 10,408 | ||||||
Long term investments | ||||||||
Excess cash | 3,423 | 10,408 | ||||||
Stockholders' equity | (1,199) | 23,536 | ||||||
Invested Capital | 6,384 | 491 | ||||||
ROIC | 1,506.10% | |||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 1,982 | 1,480 | ||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | 105 | (8,729) | ||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||